



Oriel

Creating the centre for
advancing eye health

Oriel Board update


22 September 2022



Overview

- The Oriel programme
- Revised governance
- Approval of the Full Business Case (FBC)
- Progress update
- Key risks


Oriel timeline



Oriel
Creating the centre for
advancing eye health

Oriel Governance

Partners Assurance




Partner Exec's





Tier 3



Tier 2



Tier 1



Membership of Tier 3 Boards

- The JDV Board will have four voting members:
 - Louise Hardy, Independent Chair
 - Alan Thompson, UCL Dean of Brain Sciences
 - Martin Kuper, Chief executive of Moorfields
 - Jonathan Wilson, CFO of Moorfields
- Membership of the JDV Board will also include the UCL and Moorfields SROs and estates leads. A member of NHP will also attend the JDV
- The Oriel Executive Board will continue to be co-chaired by the UCL and Moorfields SROs. Membership has been expanded to include UCL and Moorfields IT leads as well as Moorfields' Associate director of Excellence Delivery
- The Oriel Advisory Groups for patients, partners and staff remain key groups, alongside the Design User Groups
- From 17 October 2022, the Moorfields SRO will be Jon Spencer, chief operating officer



Oriel
Creating the centre for
advancing eye health

Progress update

- Our work on the green line continues, supported by our Advisory Groups. We hosted an event on 9 September to walk the route from Kings Cross to St Pancras which was attended by c40 members of our patient, partner and staff Advisory Groups
- The design team are finalising their programme for RIBA Stage 4 and will start to meet with users in the Autumn
- The final S106 Agreement has been signed by Camden & Islington NHS Foundation Trust and submitted to LB Camden. This finalises planning permission for the new Oriel centre
- An Early Works Agreement has been signed with Oriel's preferred contractor
- Legal agreements to allow Oriel to take early vacant possession of the St Pancras site are being finalised – this will allow our preferred contractor to occupy part of the site and start enabling works in October 2022



Oriel
Creating the centre for
advancing eye health

Key risks

Risk	Mitigation	Update
Regulator decision making – risk that Moorfields business case is delayed	Active engagement with NHSE/I, DHSC and HMT on timelines for business case submission and approval dates	Engagement ongoing
Securing St Pancras site vacant possession – risk that this is delayed	Active engagement with Camden & Islington; NCL ICS; London Region team	Engagement ongoing
Contractor procurement – risk that tender prices do not align with OBC assumptions	Completion of contractor procurement process and confirmation of preferred bidder, with confirmed price by December 2021	Final tender report approved at Oriel Joint Executive Board Likely to be key area of Regulator review